Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
Raffaella LionettiVincenza CalvarusoPaola PiccoloRossella Letizia MancusiChiara MazzarelliStefano FagiuoliMarzia MontalbanoIlaria LenciPaola CarraiGiovanni GuaraldiUbaldo Visco-ComandiniMartina MilanaMarco BiolatoLaura LoiaconoGiovanna ValenteAntonio CraxìMario AngelicoGianpiero D'offiziPublished in: Clinical transplantation (2017)
An extended course of SOF plus DCV for 24 weeks, with or without RBV, is effective and well tolerated for the treatment of post-LT HCV recurrence with severe fibrosis.